IMMvention Therapeutix is a biotechnology company developing novel small molecule pan-inflammasome inhibitors for inflammatory diseases.
IMMvention Therapeutix has raised $2.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2023.
IMMvention Therapeutix's investors include North Carolina Biotechnology Center.
IMMvention Therapeutix is headquartered in Chapel Hill, United States.
IMMvention Therapeutix is a biotechnology company developing novel small molecule pan-inflammasome inhibitors for inflammatory diseases.
IMMvention Therapeutix is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IMMvention Therapeutix — Funding & Investors." VCBacked, January 9, 2023, https://www.vcbacked.co/company/immvention-therapeutix. Accessed August 15, 2026.
VCBacked. (2023). IMMvention Therapeutix — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/immvention-therapeutix
{{cite web |title=IMMvention Therapeutix — Funding & Investors |url=https://www.vcbacked.co/company/immvention-therapeutix |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated